Protection against lethal enterovirus 71 challenge in mice by a recombinant vaccine candidate containing a broadly cross-neutralizing epitope within the VP2 EF loop

Theranostics

Volumn 4, Issue 5, 2014, Pages 498-513

  Xu, Longfa ^a   He, Delei ^a   Li, Zhiqun ^a   Zheng, Jun ^a   Yang, Lisheng ^a   Yu, Miao ^a   Yu, Hai ^a   Chen, Yixin ^a   Que, Yuqiong ^a   Shih, James Wai Kuo ^a   Liu, Gang ^a   Zhang, Jun ^a   Zhao, Qinjian ^a   Cheng, Tong ^a   Xia, Ningshao ^a  

^a XIAMEN UNIVERSITY   (China)

Author keywords

Cross neutralizing linear epitope; Epitope peptide vaccine; Human enterovirus 71; Therapeutic antibodies; VP2 EF loop

Indexed keywords

EPITOPE; HEPATITIS B CORE ANTIGEN; HEPATITIS B CORE ANTIGEN VP2 FUSION PROTEIN; HYBRID PROTEIN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; CROSS REACTION; DRUG BINDING; EF LOOP; ENTEROVIRUS 71; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HAND FOOT AND MOUTH DISEASE; IMMUNOPROPHYLAXIS; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PASSIVE IMMUNIZATION; PASSIVE TRANSPORT; PROTEIN STRUCTURE; RECEPTOR BINDING; STRUCTURE ANALYSIS;

CROSS-NEUTRALIZING LINEAR EPITOPE; EPITOPE PEPTIDE VACCINE.; HUMAN ENTEROVIRUS 71; THERAPEUTIC ANTIBODIES; VP2 EF LOOP;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; ENTEROVIRUS A, HUMAN; EPITOPES, B-LYMPHOCYTE; FEMALE; HAND, FOOT AND MOUTH DISEASE; MICE; MICE, INBRED BALB C; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VACCINES, SYNTHETIC; VIRAL STRUCTURAL PROTEINS; VIRAL VACCINES;

EID: 84902528771     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.7457     Document Type: Article

References (51)

1. Patel KP, Bergelson JM. Receptors identified for hand, foot and mouth virus. Nat Med. 2009; 15: 728-9.
2. Hagiwara A, Tagaya I, Yoneyama T. Epidemic of hand, foot and mouth disease associated with enterovirus 71 infection. Intervirology. 1978; 9: 60-3.
3. Ishimaru Y, Nakano S, Yamaoka K, Takami S. Outbreaks of hand, foot, and mouth disease by enterovirus 71. High incidence of complication disorders of central nervous system. Arch Dis Child. 1980; 55: 583-8.
4. Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 2010; 9:1097-105.
5. Xu J, Qian Y, Wang S, Serrano JM, Li W, Huang Z, et al. EV71: an emerging infectious disease vaccine target in the Far East? Vaccine. 2010; 28: 3516-21.
6. Chumakov M, Voroshilova M, Shindarov L, Lavrova I, Gracheva L, Koroleva G, et al. Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in Bulgaria. Arch Virol. 1979; 60: 329-40.
7. Nagy G, Takatsy S, Kukan E, Mihaly I, Domok I. Virological diagnosis of enterovirus type 71 infections: experiences gained during an epidemic of acute CNS diseases in Hungary in 1978. Arch Virol. 1982; 71: 217-27.
8. Chan LG, Parashar UD, Lye MS, Ong FG, Zaki SR, Alexander JP, et al. Deaths of children during an outbreak of hand, foot, and mouth disease in sarawak, malaysia: clinical and pathological characteristics of the disease. For the Outbreak Study Group. Clin Infect Dis. 2000; 31: 678-83.
9. Chang LY. Enterovirus 71 in Taiwan. Pediatr Neonatol. 2008; 49: 103-12.
10. Cardosa MJ, Perera D, Brown BA, Cheon D, Chan HM, Chan KP, et al. Molecular epidemiology of human enterovirus 71 strains and recent outbreaks in the Asia-Pacific region: comparative analysis of the VP1 and VP4 genes. Emerg Infect Dis. 2003; 9: 461-8.
11. Wang X, Peng W, Ren J, Hu Z, Xu J, Lou Z, et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat Struct Mol Biol. 2012; 19: 424-9.
12. Plevka P, Perera R, Cardosa J, Kuhn RJ, Rossmann MG. Crystal Structure of Human Enterovirus 71. Science. 2012; doi:10.1126/science.1218713.
13. Rossmann MG, Arnold E, Erickson JW, Frankenberger EA, Griffith JP, Hecht HJ, et al. Structure of a human common cold virus and functional relationship to other picornaviruses. Nature. 1985; 317: 145-53.
14. Foo DG, Alonso S, Phoon MC, Ramachandran NP, Chow VT, Poh CL. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res. 2007; 125: 61-8.
15. Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, Chang JY, et al. Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine. 2011; 29: 4362-72.
16. Fiore L, Ridolfi B, Genovese D, Buttinelli G, Lucioli S, Lahm A, et al. Poliovirus Sabin type 1 neutralization epitopes recognized by immunoglobulin A monoclonal antibodies. J Virol. 1997; 71: 6905-12.
17. Buttinelli G, Donati V, Ruggeri FM, Joki-Korpela P, Hyypia T, Fiore L. Antigenic sites of coxsackie A9 virus inducing neutralizing monoclonal antibodies protective in mice. Virology. 2003; 312: 74-83.
18. Bubeck D, Filman DJ, Cheng N, Steven AC, Hogle JM, Belnap DM. The structure of the poliovirus 135S cell entry intermediate at 10-angstrom resolution reveals the location of an externalized polypeptide that binds to membranes. J Virol. 2005; 79: 7745-55.
19. Lin J, Cheng N, Chow M, Filman DJ, Steven AC, Hogle JM, et al. An externalized polypeptide partitions between two distinct sites on genome-released poliovirus particles. J Virol. 2011; 85: 9974-83.
20. Zhang D, Lu J. Enterovirus 71 vaccine: close but still far. Int J Infect Dis. 2010; 14: e739-43.
21. Foo DG, Macary PA, Alonso S, Poh CL. Identification of human CD4 T-cell epitopes on the VP1 capsid protein of enterovirus 71. Viral Immunol. 2008; 21:215-24.
22. Foo DG, Alonso S, Chow VT, Poh CL. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect. 2007; 9: 1299-306.
23. Kiener TK, Jia Q, Lim XF, He F, Meng T, Chow VT, et al. Characterization and specificity of the linear epitope of the enterovirus 71 VP2 protein. Virol J. 2012; 9: 55.
24. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975; 256: 495-7.
25. Galfre G, Howe SC, Milstein C, Butcher GW, Howard JC. Antibodies to major histocompatibility antigens produced by hybrid cell lines. Nature. 1977; 266:550-2.
26. Luo WX, Zhang J, Yang HJ, Li SW, Xie XY, Pang SQ, et al. [Construction and application of an Escherichia coli high effective expression vector with an enhancer]. Sheng Wu Gong Cheng Xue Bao. 2000; 16: 578-81.
27. Yang HJ, Chen M, Cheng T, He SZ, Li SW, Guan BQ, et al. Expression and immunoactivity of chimeric particulate antigens of receptor binding site-core antigen of hepatitis B virus. World J Gastroenterol. 2005; 11: 492-7.
28. Xu F, Yan Q, Wang H, Niu J, Li L, Zhu F, et al. Performance of detecting IgM antibodies against enterovirus 71 for early diagnosis. PLoS One. 2010; 5:e11388.
29. Xu F, He D, He S, Wu B, Guan L, Niu J, et al. Development of an IgM-capture ELISA for Coxsackievirus A16 infection. J Virol Methods. 2011; 171: 107-10.
30. Wang YF, Chou CT, Lei HY, Liu CC, Wang SM, Yan JJ, et al. A mouse-adapted enterovirus 71 strain causes neurological disease in mice after oral infection. J Virol. 2004; 78: 7916-24.
31. Chen CS, Yao YC, Lin SC, Lee YP, Wang YF, Wang JR, et al. Retrograde axonal transport: a major transmission route of enterovirus 71 in mice. J Virol. 2007; 81: 8996-9003.
32. Ye X, Ku Z, Liu Q, Wang X, Shi J, Zhang Y, et al. Chimeric Virus-Like Particle Vaccines Displaying Conserved Enterovirus 71 Epitopes Elicit Protective Neutralizing Antibodies in Mice through Divergent Mechanisms. J Virol. 2014; 88: 72-81.
33. Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, Shimizu H. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med. 2009; 15: 794-7.
34. Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, Takemura T, et al. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med. 2009; 15: 798-801.
35. Yang SL, Chou YT, Wu CN, Ho MS. Annexin II binds to capsid protein VP1 of enterovirus 71 and enhances viral infectivity. J Virol. 2011; 85: 11809-20.
36. Chen P, Song Z, Qi Y, Feng X, Xu N, Sun Y, et al. Molecular determinants of enterovirus 71 viral entry: cleft around GLN-172 on VP1 protein interacts with variable region on scavenge receptor B 2. J Biol Chem. 2012; 287: 6406-20.
37. Che Z, Olson NH, Leippe D, Lee WM, Mosser AG, Rueckert RR, et al. Antibody- mediated neutralization of human rhinovirus 14 explored by means of cryoelectron microscopy and X-ray crystallography of virus-Fab complexes. J Virol. 1998; 72: 4610-22.
38. Xiao C, Bator CM, Bowman VD, Rieder E, He Y, Hebert B, et al. Interaction of coxsackievirus A21 with its cellular receptor, ICAM-1. J Virol. 2001; 75:2444-51.
39. Xiao C, Bator-Kelly CM, Rieder E, Chipman PR, Craig A, Kuhn RJ, et al. The crystal structure of coxsackievirus A21 and its interaction with ICAM-1. Structure. 2005; 13: 1019-33.
40. Belnap DM, McDermott BM, Jr., Filman DJ, Cheng N, Trus BL, Zuccola HJ, et al. Three-dimensional structure of poliovirus receptor bound to poliovirus. Proc Natl Acad Sci U S A. 2000; 97: 73-8.
41. He Y, Bowman VD, Mueller S, Bator CM, Bella J, Peng X, et al. Interaction of the poliovirus receptor with poliovirus. Proc Natl Acad Sci U S A. 2000; 97:79-84.
42. He Y, Chipman PR, Howitt J, Bator CM, Whitt MA, Baker TS, et al. Interaction of coxsackievirus B3 with the full length coxsackievirus-adenovirus receptor. Nat Struct Biol. 2001; 8: 874-8.
43. Rossmann MG, He Y, Kuhn RJ. Picornavirus-receptor interactions. Trends Microbiol. 2002; 10: 324-31.
44. Page GS, Mosser AG, Hogle JM, Filman DJ, Rueckert RR, Chow M. Three-dimensional structure of poliovirus serotype 1 neutralizing determinants. J Virol. 1988; 62: 1781-94.
45. Miyamura K, Nishimura Y, Abo M, Wakita T, Shimizu H. Adaptive mutations in the genomes of enterovirus 71 strains following infection of mouse cells expressing human P-selectin glycoprotein ligand-1. J Gen Virol. 2011; 92:287-91.
46. Clarke BE, Newton SE, Carroll AR, Francis MJ, Appleyard G, Syred AD, et al. Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. Nature. 1987; 330: 381-4.
47. Schotsaert M, De Filette M, Fiers W, Saelens X. Universal M2 ectodomain- based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines. 2009; 8: 499-508.
48. Walther M, Dunachie S, Keating S, Vuola JM, Berthoud T, Schmidt A, et al. Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. Vaccine. 2005; 23: 857-64.
49. Milich DR, McLachlan A. The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen. Science. 1986; 234:1398-401.
50. Pumpens P, Borisova GP, Crowther RA, Grens E. Hepatitis B virus core particles as epitope carriers. Intervirology. 1995; 38: 63-74.
51. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov. 2010; 9: 767-74.